Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar, On behalf of the Israel Lung Cancer Group
Abstract
:
Topics & Concepts
PembrolizumabMedicineLung cancerInternal medicineDiscontinuationChemotherapyGastroenterologyCancerOncologyPropensity score matchingImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment